Page last updated: 2024-11-12

(4-24)-ply(a)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

peptide-Gly-Leu-amide: 21-amino acid peptide from skin secretion of Xenopus laevis; amino acid sequence given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16131010
CHEMBL ID1240715
MeSH IDM0133158

Synonyms (11)

Synonym
pgla
(4-24)-ply(a)
peptide-gly-leu-amide
pyl(a), 4-24-
pgl(a)
gla peptide
l-leucinamide, glycyl-l-methionyl-l-alanyl-l-seryl-l-lysyl-l-alanylglylcyl-l-alanyl-l-isoleucyl-l-alanylglycyl-l-lysyl-l-isoleucyl-l-alanyl-l-lysyl-l-valyl-l-alanyl-l-leucyl-l-lysyl-l-alanyl-
gmaskagaiagkiakvalkal-nh2
CHEMBL1240715
AKOS024259107
l-leucinamide,glycyl-l-methionyl-l-alanyl-l-seryl-l-lysyl-l-alanylglycyl-l-alanyl-l-isoleucyl-l-alanylglycyl-l-lysyl-l-isoleucyl-l-alanyl-l-lysyl-l-valyl-l-alanyl-l-leucyl-l-lysyl-l-alanyl-

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"Heparin sodium (HS)-loaded polylactic-co-glycolic acid-D-α-tocopheryl polyethylene glycol 1000 succinate (PLGA-TPGS) nanoparticles (HPTNs) were prepared as a sustained and targeting delivery carrier and combined with emodin (EMO)-loaded PLGA-TPGS nanoparticles (EPTNs), which were investigated previously to form a combination therapy system for the treatment of liver cancer."( Emodin-Loaded PLGA-TPGS Nanoparticles Combined with Heparin Sodium-Loaded PLGA-TPGS Nanoparticles to Enhance Chemotherapeutic Efficacy Against Liver Cancer.
Deng, S; Gao, D; Gao, M; Gao, X; Liu, H; Lv, L; Ma, C; Tian, Y; Wang, C; Xu, H; Zhang, C, 2016
)
0.43
" The apoptosis of HepG2 cells induced by EPTNs in combination with HPTNs was determined by Annexin V-FITC staining and PI labelling."( Emodin-Loaded PLGA-TPGS Nanoparticles Combined with Heparin Sodium-Loaded PLGA-TPGS Nanoparticles to Enhance Chemotherapeutic Efficacy Against Liver Cancer.
Deng, S; Gao, D; Gao, M; Gao, X; Liu, H; Lv, L; Ma, C; Tian, Y; Wang, C; Xu, H; Zhang, C, 2016
)
0.43
" EPTNs combined with HPTNs induced HepG2 cell apoptosis with synergistic effects."( Emodin-Loaded PLGA-TPGS Nanoparticles Combined with Heparin Sodium-Loaded PLGA-TPGS Nanoparticles to Enhance Chemotherapeutic Efficacy Against Liver Cancer.
Deng, S; Gao, D; Gao, M; Gao, X; Liu, H; Lv, L; Ma, C; Tian, Y; Wang, C; Xu, H; Zhang, C, 2016
)
0.43
" A case study was performed to observe the regenerative outcomes of the surgical repair of long-distance peripheral nerve defects in the upper arm with chitosan-poly(glycolide-co-lactide) (PGLA) nerve grafts combined with bone marrow mononuclear cells (BMMCs)."( Combined Use of Chitosan-PGLA Nerve Grafts and Bone Marrow Mononuclear Cells to Repair a 50-mm-long Median Nerve Defect Combined with an 80-mm-long Ulnar Nerve Defect in the Human Upper Arm.
Deng, A; Gu, J; Gu, X; Liu, H; Xu, L; Yi, S, 2022
)
0.72
"These results suggest that chitosan-PGLA nerve grafts combined with BMMCs could effectively repair long-distance nerve defects and achieve good clinical results."( Combined Use of Chitosan-PGLA Nerve Grafts and Bone Marrow Mononuclear Cells to Repair a 50-mm-long Median Nerve Defect Combined with an 80-mm-long Ulnar Nerve Defect in the Human Upper Arm.
Deng, A; Gu, J; Gu, X; Liu, H; Xu, L; Yi, S, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" The dose-response curves differed widely for these peptides, making it difficult to rank them into an activity order over the whole concentration range."( Analyses of dose-response curves to compare the antimicrobial activity of model cationic alpha-helical peptides highlights the necessity for a minimum of two activity parameters.
Gerstner, GD; Kulenkampff, J; Rautenbach, M; Vlok, NM; Westerhoff, HV, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID559751Antibacterial activity against Escherichia coli DSM 498 in presence of silver nanoparticles2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559753Antibacterial activity against Enterobacter helveticus DSM 18396 in presence of silver nanoparticles2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559757Antibacterial activity against Bacillus subtilis DSM 347 in presence of silver nanoparticles2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559744Antibacterial activity against Enterobacter helveticus DSM 18396 in presence of silver nitrate2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559738Antibacterial activity against Pseudomonas fluorescens DSM 500902009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559742Antibacterial activity against Escherichia coli DSM 498 in presence of silver nitrate2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559741Antibacterial activity against Micrococcus luteus DSM 17902009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559748Antibacterial activity against Bacillus subtilis DSM 347 in presence of silver nitrate2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559745Antibacterial activity against Aeromonas bestiarum DSM 13956 in presence of silver nitrate2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559759Antibacterial activity against Micrococcus luteus DSM 1790 in presence of silver nanoparticles2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559749Antibacterial activity against Kocuria rhizophila DSM 348 in presence of silver nitrate2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559734Antibacterial activity against Acinetobacter calcoaceticus DSM 5862009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559747Antibacterial activity against Pseudomonas fluorescens DSM 50090 in presence of silver nitrate2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID511694Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.
AID559758Antibacterial activity against Kocuria rhizophila DSM 348 in presence of silver nanoparticles2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559746Antibacterial activity against Proteus myxofaciens DSM 4482 in presence of silver nitrate2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559735Antibacterial activity against Enterobacter helveticus DSM 183962009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559740Antibacterial activity against Kocuria rhizophila DSM 3482009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559743Antibacterial activity against Acinetobacter calcoaceticus DSM 586 in presence of silver nitrate2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID511695Cytotoxicity against human CEM-SS cells infected with HIV1 3B after 6 days by XTT assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.
AID559736Antibacterial activity against Aeromonas bestiarum DSM 139562009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID561113Antibacterial activity against Escherichia coli DSM 4982009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559750Antibacterial activity against Micrococcus luteus DSM 1790 in presence of silver nitrate2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559755Antibacterial activity against Proteus myxofaciens DSM 4482 in presence of silver nanoparticles2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559754Antibacterial activity against Aeromonas bestiarum DSM 13956 in presence of silver nanoparticles2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559752Antibacterial activity against Acinetobacter calcoaceticus DSM 586 in presence of silver nanoparticles2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559760Toxicity in human erythrocytes assessed as hemolysis by serial dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559739Antibacterial activity against Bacillus subtilis DSM 3472009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559737Antibacterial activity against Proteus myxofaciens DSM 44822009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
AID559756Antibacterial activity against Pseudomonas fluorescens DSM 50090 in presence of silver nanoparticles2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (115)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (6.96)18.7374
1990's14 (12.17)18.2507
2000's31 (26.96)29.6817
2010's54 (46.96)24.3611
2020's8 (6.96)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.16 (24.57)
Research Supply Index4.79 (2.92)
Research Growth Index4.95 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.85%)5.53%
Reviews3 (2.54%)6.00%
Case Studies2 (1.69%)4.05%
Observational1 (0.85%)0.25%
Other111 (94.07%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]